

ASX ANNOUNCEMENT

Medical Expert Appointed NED

- **Dr Dominic Barnes MBBS, MMedSc, MBA, FAICD appointed Independent Non-Executive Director of Recce Ltd**

Perth, Western Australia, 16 May 2016 – Recce Ltd (ASX: RCE), the developers of a new class of patented drugs targeted at antibiotic and anti-cancer human applications, is pleased to announce the appointment of Dr Dominic Barnes as an Independent Non-Executive Director.

Recce plans the submission of an IND application to the FDA (giving approval for human trials of its RECCE® 327 antibiotic) around 30 June 2017 – and therefore the appointment of Dr Barnes, who has successfully supervised some 20 of such human trials, is especially timely and commensurate with the Company's progress.

Enhancing his qualifications as a practicing medical doctor, Dr Barnes has a Master of Business Administration from Macquarie University, a Master of Drug Development from the University of New South Wales and has completed an Executive Development Program at the prestigious Wharton School of Management, USA, on the East Coast where Recce plans to manufacture its product, and Dr Barnes has developed an esteemed business and medical reputation.

During his career, Dr Barnes has had directorships and senior regulatory appointments with leading global pharmaceutical companies: Shire, AstraZeneca and Johnson & Johnson; he is also a leading member of medical, government and academic institutions in Australia.

Dr Graham Melrose, Executive Chairman, and his fellow directors are very pleased to welcome Dr Dominic Barnes.

For further information please visit www.recce.com.au or contact:

Investor Relations

Peter Williams
CFO & Company Secretary
Recce Ltd
Tel: +61 8 9253 9800

Media Communication

Karen Oswald - karen.oswald@markocommunications.com.au
Gary Buchholz – gary@markocommunications.com.au
Marko Communications
Tel: +61 423 602 353

About Recce Ltd

Recce Ltd (ASX: RCE) is a world leader in synthetic polymer-antibiotics. The RECCE® antibiotics have been synthesized by an extremely simple and economic method.

RECCE® antibiotics have shown in laboratory tests that they have continued activity against bacteria including superbugs, even after repeated use.

Recce is positioned to achieve milestones in both pre-clinical trials for FDA purposes and the development of the manufacture of RECCE® antibiotics.

ASX: RCE

Head Office - Perth Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9253 9800 **F** +61 (8) 9253 9899
Sydney Office Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 **T** +61 (2) 8075 4707
Washington Office 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA



The discovery of RECCE® 327's capabilities against cancer (as well as bacteria-superbugs) has greatly increased the value of the Company's technology, especially in view of synergism between the anti-cancer and antibiotic properties.

Recce has granted patents in Australia, United States, Europe, Japan and China – giving it legal monopolies and potential financial returns from manufacture and distribution in some 80% of the world's pharmaceutical markets.

